Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1]. Group 1: Allegations and Class Period - The class period for the allegations is from June 22, 2023, to June 24, 2025 [1]. - Allegations include that Sarepta Therapeutics made materially false and misleading statements about ELEVIDYS, which is a prescription gene therapy for Duchenne muscular dystrophy [1]. - Specific claims include significant safety risks associated with ELEVIDYS, failure of trial protocols to detect severe side effects, and the potential halting of recruitment and dosing in trials due to adverse events [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by August 25, 2025, to potentially be appointed as lead plaintiffs [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case [2]. - Participation in the case incurs no cost or obligation for shareholders [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the safety of its product ELEVIDYS [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Sarepta between June 22, 2023, and June 24, 2025, to discuss their legal rights [1]. - There is a deadline of August 25, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Sarepta [2]. - The complaint alleges that Sarepta and its executives made false statements regarding the safety of ELEVIDYS, which posed significant risks to patients [4]. Group 2: Stock Price Impact - Following a safety update on March 18, 2025, where a patient died after treatment with ELEVIDYS, Sarepta's stock price fell by $27.81, or 27.44%, closing at $73.54 [5]. - On April 4, 2025, after the company disclosed that EU authorities requested a review of the death, the stock price dropped by $4.18, or 7.13%, closing at $54.43 [6]. - A second patient death was reported on June 15, 2025, leading to a significant stock price decline of $15.24, or 42.12%, closing at $20.91 [7][8]. - Following an FDA Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks, the stock price fell by $1.52, or 8.01%, closing at $17.46 [8][9]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=155065&from=3 CLASS PERIOD: June 22, 2 ...

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly making false and misleading statements regarding its gene therapy product ELEVIDYS during the specified Class Period [1][2]. Allegations in the Complaint - Sarepta is accused of misrepresenting the safety of ELEVIDYS, despite serious risks associated with the product [7]. - The company allegedly failed to detect or disclose severe adverse events during clinical trials [7]. - It is claimed that Sarepta withheld material information that led to halted dosing, increased regulatory scrutiny, and suspension of shipments [7]. - The company is also said to have lacked a reasonable basis for positive statements about ELEVIDYS's safety and potential for expanded use [7]. Key Events and Stock Impact - Investors who purchased Sarepta securities during the Class Period and suffered losses have until August 25, 2025, to request the Court to appoint them as lead plaintiff [3].

LOS ANGELES, July 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the federal securities laws.Shareholders who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.CASE DETAILS:  The complaint alleges that the Company made false and misleading statements to the ma ...

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during a specified class period [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including its gene therapy product, ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, inadequate trial protocols to detect severe side effects, and the potential for halting recruitment and dosing due to adverse events [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock price drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the deaths related to ELEVIDYS, causing an additional stock decline of over 8% [7]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Sarepta securities during the class period to seek appointment as lead plaintiff, representing the interests of the class [8].

NEW YORK, July 1, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) and certain of its officers.Class DefinitionThis lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sarepta ...

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and revenue outlook of its gene therapy ELEVIDYS, intended for treating Duchenne muscular dystrophy [1][3]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing gene therapies, specifically ELEVIDYS, for Duchenne muscular dystrophy [3]. Allegations - The lawsuit claims that Sarepta made materially false and misleading statements about ELEVIDYS, leading investors to believe it was a safe therapy with no hindrances to broader application approval [3]. - Specific allegations include: - ELEVIDYS posed significant safety risks to patients [3]. - Trial protocols failed to detect severe side effects [3]. - Adverse events would lead to halted recruitment and dosing in trials, attracting regulatory scrutiny [3]. - Positive statements made by the company lacked a reasonable basis [3]. Stock Price Impact - Following a safety update on March 18, 2025, Sarepta's stock price fell by $27.81 per share (27.44%) to close at $73.54 [4]. - On April 4, 2025, after disclosing regulatory requests, the stock price dropped by $4.18 per share (7.13%) to close at $54.43 [4]. - A second patient death reported on June 15, 2025, caused the stock to fall by $15.24 per share (42.12%) to close at $20.91 [4]. - The FDA's safety communication on June 24, 2025, led to a further decline of $1.52 per share (8.01%) to close at $17.46 [4].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Allegations - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including the inability of trial protocols to detect severe side effects and the potential for adverse events to halt recruitment and dosing in clinical trials [2]. - Specific allegations include that the severity of adverse events would attract regulatory scrutiny and increase risks surrounding the therapy's approvals [2]. Stock Price Impact - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price dropped by $27.81, or 27.44%, closing at $73.54 [3]. - On June 15, 2025, after disclosing a second patient death due to acute liver failure and announcing a suspension of shipments for non-ambulatory patients, the stock fell by $15.24, or 42.12%, closing at $20.91 [3]. - The FDA's investigation announcement on June 24, 2025, regarding the risk of acute liver failure led to an additional stock price decline of $1.52, or 8.01%, closing at $17.46 [4]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file a motion by August 25, 2025, although participation is not required to be eligible for recovery [5].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for alleged violations of securities laws, specifically related to misleading statements about its ELEVIDYS therapy and revenue outlook [1][4]. Group 1: Lawsuit Details - The lawsuit is based on allegations that Sarepta made false and misleading statements regarding the safety and approval potential of its ELEVIDYS therapy [4]. - Investors who purchased Sarepta's securities between June 22, 2023, and June 24, 2025, are encouraged to participate in the class action before the deadline of August 25, 2025 [2]. - The class has not yet been certified, meaning that potential class members are not currently represented by an attorney [3]. Group 2: Impact on Investors - The misleading statements led investors to believe in a strong growth potential for the ELEVIDYS therapy, which ultimately resulted in financial damages when the truth was revealed [4]. - The Schall Law Firm specializes in securities class action lawsuits and aims to represent investors seeking to recover losses incurred due to the alleged misconduct [5].